Novartis' Aimovig shows superior tolerability, efficacy in late-stage migraine study

• Novartis (NYSE:NVS) announces that HER-MES, the first Phase IV, randomized, double-dummy, study of Aimovig (erenumab) against topiramate, an anticonvulsant, in patients with episodic and chronic migraine met its primary and secondary endpoints.
• The results showed that Aimovig had a superior tolerability and efficacy profile than topiramate, with less discontinuation over the course of the 24-week treatment phase.
• Aimovig also demonstrated superior efficacy, with a greater proportion of patients achieving at least 50% reduction in their monthly migraine days (MMDs).
• The safety profile in the HER-MES study was generally consistent with those seen in previous Aimovig clinical trials.
• The study enrolled 777 adult patients suffering from ≥ 4 MMDs.
• Additional findings and detailed results will be presented at an upcoming scientific congress.
• Novartis and Amgen (NASDAQ:AMGN) are co-commercializing Aimovig in the US. The Companies inked deal in September 2015 to develop and commercialize neuroscience treatments.
• https://seekingalpha.com/news/3629470-novartis-aimovig-shows-superior-tolerability-and-efficacy-in-late-stage-migraine-study